New SCM Facility to Begin Production After MHRA Approval

By Dan Stanton

- Last updated on GMT

SCM PHarma's new plant gets regulatory thumbs up
SCM PHarma's new plant gets regulatory thumbs up
SCM Pharma says its new contract manufacturing facility will cater for clients upscaling towards commercial production and the trend towards orphan drugs.

The Newburn facility near Newcastle, UK cost £6m ($10m) to construct and yesterday the company announced it had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to begin commercial production.

Newburn will ensure the company has the capacity to deal with increasing demand coming from clients at SCM’s nearby clinical manufacturing facility - which deals "with novel new clinical trial projects that need developing and small scale sterile manufacturing"​ - looking to scale up towards commercial production, Managing Director at SCM Dianne Sharp told Outsourcing-Pharma.com.

Furthermore, she added the new facility will allow the firm to deal with licensed products in niche markets on the lower end of the volume scale.

“This has been our sweet spot for several commercial clients over the last few years and we have seen increasing demand in-line with the trend towards personalised medicines.”

Operations are set to begin at the back-end of summer with an oral syringe filling project for an undisclosed EU client with a dedicated suite put in place along with filling and packaging equipment.

According to Sharp, this reinforces the manufacturing progression that the company hopes to provide with the facility:

“We carried out the clinical supply of this product and are now the commercial supply partner with Newburn at the hub of the operation.”

Last month the company was named as commercial supplier for BTG’s​ candidate treatment for varicose veins, Varisolve, which – if approval is granted – could prove lucrative for both BTG and SCM.

The 26,000 sq ft site includes a range of packaging and labeling areas, temperature controlled warehousing, raw materials and engineering preparation, visual inspection and leak testing, and has led to a 45% increase in staff at SCM, jumping from 75 to 110.

Related news

Show more

Related product

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers